The Singapore company building digital twins of human health - software that reads the trajectory of a chronic disease before a patient ever feels it.
MESH BIO, HQ on Sin Ming Lane, Singapore. A health deep-tech founded by Andrew Wu and Arsen Batagov in 2018 - photographed here as the mark it puts on hospital dashboards across Southeast Asia.
In most clinics, a health screening is a rear-view mirror. It tells you what your cholesterol was on the morning of the blood draw. Mesh Bio, a health deep-tech based on Sin Ming Lane in Singapore, was built on a different premise - that the same data, read the right way, can point forward.
Founded in 2018 by Andrew Wu and Arsen Batagov, the company develops predictive analytics and clinical decision-support software for the management and prevention of chronic disease. Its models draw on multidimensional patient data - blood tests, heart rate, weight and more - to build what the company calls a digital twin: a virtual, data-driven model of a person's state of health that clinicians can use to see where a disease is heading.
The conditions in its sights are the ones that quietly do the most damage: diabetes, chronic kidney disease, cardiovascular disease, hypertension, myocardial infarction and stroke. Mesh Bio says its models can identify at-risk patients up to ten years before a clinical diagnosis would normally land.
The point is practical. Chronic, noncommunicable disease accounts for close to two-thirds of deaths in the region. You manage what you can predict - and prediction, delivered inside the clinical workflow, is the product.
An AI platform that automates health-screening report generation, risk stratification, result interpretation and referral optimization. It cuts manual report writing by up to 90%, turning hours of clinician admin into minutes and freeing staff for care.
A predictive disease-progression tool that models diabetes complications and personalizes patient risk. In October 2023 it earned clearance from Singapore's Health Sciences Authority as a Software as a Medical Device - a rare regulatory bar for prediction software.
The underlying models that build a virtual replica of a patient's metabolism from bloodwork and vitals, integrating directly with providers' electronic medical records via API to power real-time clinical decision support.
Bloodwork, vitals and history flow in from the provider's EMR through API integration.
▶A digital twin is built - a virtual model of the patient's metabolic state.
▶Disease-progression algorithms stratify risk and flag likely complications years ahead.
▶Clinicians get an automated report, decision support and referral guidance at the point of care.
Plenty of companies say "AI in healthcare." Fewer take the slow, regulated route that earns clinical trust. Mesh Bio's differentiators are the unglamorous ones - a medical-device clearance, deep EMR integration, and a workflow doctors actually adopt.
Nearest comparisons in the region include ChromX Health (breath-based screening) and Gense Technologies (medical imaging), alongside broader clinical decision-support and population-health analytics vendors. Mesh Bio's wedge is metabolic disease, read through a digital twin.
The model is B2B enterprise software. Mesh Bio licenses its analytics platform to hospitals, clinics, diagnostic labs and health-screening groups, integrating with their electronic medical records and charging through platform subscriptions and clinical-analytics use. Its coverage spans primary prevention - the routine medical checkup - through secondary prevention, where the software flags the complications of a disease already present.
That places the company in the growing intersection of healthcare AI, clinical decision support and population-health analytics, aimed squarely at Southeast Asia's rising chronic-disease burden. The expertise behind it is a blend of clinical, data-science and biochemical-engineering knowledge: CEO Andrew Wu holds a Ph.D. in biochemical engineering from University College London, and co-founder Melvin Heng brings a physician and hospital-administration background.
| Round | Amount | Date | Lead / Investors |
|---|---|---|---|
| Seed | US$1.8M | Oct 2021 | Elev8, SEEDS Capital, Citrine Capital, Tael Partners |
| Series A | US$3.5M | Jan 2024 | East Ventures (lead), Elev8, SEEDS Capital |
Andrew Wu, Arsen Batagov and Melvin Heng launch a health deep-tech to bring digital twin analytics to chronic disease care.
The company builds its predictive analytics and clinical workflow automation platform for health-screening providers.
Elev8, SEEDS Capital, Citrine Capital and Tael Partners fund the rollout of DARA across Southeast Asia and Hong Kong.
Singapore's Health Sciences Authority approves it as a Software as a Medical Device, opening hospital pilots.
Funding accelerates regional expansion of digital twin technologies for chronic disease management.
It builds AI-powered digital twin and predictive-analytics software that helps healthcare providers detect, predict and manage chronic diseases such as diabetes, kidney and cardiovascular disease earlier.
DARA, an automated health-screening and clinical decision-support platform, and HealthVector Diabetes, a regulator-approved tool that predicts diabetes complications.
It was founded in 2018 in Singapore by Andrew Wu (CEO), Arsen Batagov (CTO) and Melvin Heng.
Around US$5.3 million total - a US$1.8M seed round in 2021 and a US$3.5M Series A led by East Ventures in January 2024.
Yes - HealthVector Diabetes received Software as a Medical Device clearance from Singapore's Health Sciences Authority in October 2023 and is in pilots at hospitals including SGH and TTSH.